SymBio Pharmaceuticals Limited (TYO:4582)

SymBio Pharmaceuticals Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-	-3,806	-1,195	2,106	2,032	-4,090
Depreciation & Amortization	-	-	98	99	93.96	63.84
Other Amortization	-	-	-	-	1.95	27.02
Loss (Gain) From Sale of Assets	-	131	568	-	0.69	0.04
Stock-Based Compensation	-	-	-	-	124.27	102.38
Other Operating Activities	-	27	-377	-420	-1,048	-30.82
Change in Accounts Receivable	-	489	1,171	62	-1,741	142.29
Change in Inventory	-	54	237	-82	559.24	-944.44
Change in Accounts Payable	-	-215	-356	662	-595.78	578.36
Change in Other Net Operating Assets	-	-96	-340	-813	711.88	29.08
Operating Cash Flow	-	-3,416	-194	1,614	140.04	-4,122
Operating Cash Flow Growth	-	-	-	1052.51%	-	-
Capital Expenditures	-	-19	-204	-2	-25.45	-15.67
Sale (Purchase) of Intangibles	-	-27	-28	-45	-38.38	-133.26
Other Investing Activities	-	43	-144	-	-7.01	-11.38
Investing Cash Flow	-	-3	-376	-47	-70.85	-160.31
Issuance of Common Stock	-	709	681	630	0.9	4,256
Repurchase of Common Stock	-	-	-	-2	-68.83	-6.39
Other Financing Activities	-	-1	-1	-1	-4	-27.29
Financing Cash Flow	-	708	680	627	-71.92	4,222
Foreign Exchange Rate Adjustments	-	158	125	213	14.21	-1.5
Miscellaneous Cash Flow Adjustments	-	-	-1	14	-	-0
Net Cash Flow	-	-2,553	234	2,421	11.48	-62.2
Free Cash Flow	-	-3,435	-398	1,612	114.59	-4,138
Free Cash Flow Growth	-	-	-	1306.78%	-	-
Free Cash Flow Margin	-	-140.09%	-7.12%	16.11%	1.39%	-138.54%
Free Cash Flow Per Share	-	-76.17	-9.97	40.70	2.95	-125.59
Cash Income Tax Paid	-	-39	354	363	3.8	1.9
Levered Free Cash Flow	-	-2,055	-143.5	1,542	-226.95	-3,019
Unlevered Free Cash Flow	-	-2,055	-143.5	1,542	-226.95	-3,019
Change in Net Working Capital	80.51	-414	-498	-262.62	1,018	246.89

Updated Feb 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.